Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children.

CONCLUSIONS: PCV may protect high-risk children against pneumococcal colonization and mucosal disease by inducing mucosal antibody responses and priming for mucosal immune memory that results in mucosal immune responses after booster PPV. Saliva can be a convenient alternative sample to serum to study PCV-induced systemic IgG responses. PMID: 33121845 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33121845?dopt=Abstract

Source: Vaccine - October 26, 2020 Category: Allergy & Immunology Authors: Orami T, Ford R, Kirkham LA, Thornton R, Corscadden K, Richmond PC, Pomat WS, van den Biggelaar AHJ, Lehmann D, Neonatal Pneumococcal Conjugate Vaccine Trial team Tags: Vaccine Source Type: research